Is Cemiplimab available in stock in China and how to purchase it?

Cemiplimab (Cemiplimab) has not yet been officially launched in the domestic market, so there is currently no spot supply in the country. This drug is also not included in the medical insurance catalog, resulting in very limited ways for patients to purchase it through formal channels in China. Due to the lack of official sales channels, if domestic patients need to use cimepilimab, they usually need to obtain it through overseas purchasing agents or international pharmacies. There are certain purchase risks and legal restrictions.

In overseas markets, cimepilimab has been provided by the original manufacturer in two main versions: the US version and the European version. Common specifications are 350mg/7mL (50mg/mL). The price per box is relatively high, generally between RMB 40,000 and RMB 100,000. Price fluctuations are mainly affected by exchange rates and market supply and demand. At present, there are no generic drugs of cimepilimab in overseas markets, which means that the original drug is the only available product and is relatively expensive.

If patients consider purchasing cimeplimab through overseas channels, they should choose reputable international pharmacies or regular overseas medical institutions to avoid illegal drugs or counterfeit and shoddy products. When purchasing, you should also pay attention to the transportation conditions and shelf life of the medicine to ensure the quality and safety of the medicine. At the same time, the use of such antibody drugs requires the guidance of professional doctors to reasonably evaluate treatment options and potential risks.

Overall, cimepilimab is not available in stock in China, formal purchasing channels are limited, and the price is relatively high. In the future, if the drug is approved for marketing in China and included in medical insurance, patients will be able to obtain treatment drugs more conveniently and economically. At present, patients and their families need to pay close attention to drug approval and market dynamics, and plan treatment plans rationally.

Reference materials:https://www.libtayohcp.com/